Top

Published in:

01-07-2020 | Prostate Cancer | Original Article

Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer

Authors: Dr. Francesco Cuccia, Luca Nicosia, Rosario Mazzola, Vanessa Figlia, Niccolò Giaj-Levra, Francesco Ricchetti, Michele Rigo, Claudio Vitale, Stefanie Corradini, Ruggero Ruggieri, Filippo Alongi

Published in: Strahlentherapie und Onkologie | Issue 7/2020

Abstract

Background and objective

The optimal management of prostate cancer (PC) recurrences after definitive or postoperative radiotherapy (RT) is still controversial. The aim of the present retrospective study was to report the preliminary clinical results and toxicity of a mono-institutional series of patients re-irradiated with linac-based SBRT in recurrent prostate cancer.

Methods

Inclusion criteria were previous definitive or adjuvant/salvage RT, evidence of biochemical recurrence and radiological detection of local relapse (Magnetic Resonance Imaging or PSMA/choline-Positron Emission Tomography), and IPSS <10. Toxicity was assessed according to Common Terminology Criteria for Adverse Events v4.0.

Results

Between 12/2014 and 12/2019, 24 patients with median age 75 years (65–89) underwent re-RT for PC recurrence. Median follow-up was 21 months (2–68). The recurrences occurred in 13 cases within the prostate and in 11 cases within the prostate bed. All patients were treated with SBRT to a median total dose of 30 Gy (25–36 Gy) in 5–6 fractions, and simultaneous androgen deprivation therapy was administered in 4 patients. Acute toxicity was G1 in 8.3% and G2 in 12.5% for genitourinary (GU), no acute gastrointestinal (GI) toxicity occurred. Concerning late side effects, 19.7% of patients were found to have ≥G2 GU toxicity, including one G3 urethral stenosis. Only one case of G1 late GI toxicity occurred and no ≥G2. The 2‑year overall survival was 95%. The 1‑ and 2‑year biochemical relapse-free survival (BRFS) and progression-free survival (PFS) rates were 80 and 54.9%, respectively.

Conclusion

Despite of the heterogeneity of the sample, linac-based SBRT as a salvage treatment in previously irradiated locally recurrent PC patients seems to be a safe and feasible treatment option. Long-term data are pending.

Mazzola R, Cuccia F, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Pasinetti N, Salgarello M, Alongi F (2019) New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? Transl Androl Urol 8(Suppl 5):S538–S541. https://doi.org/10.21037/tau.2019.12.34 CrossRefPubMedPubMedCentral

De Bari B, Mazzola R, Aiello D, Aloi D, Gatta R, Corradini S, Salgarello M, Alongi F (2019) (68Ga)-PSMA-PET/CT for the detection of postoperative prostate cancer recurrence: Possible implications on treatment volumes for radiation therapy. Cancer Radiother 23(3):194–200. https://doi.org/10.1016/j.canrad.2018.09.003 CrossRefPubMed

De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F (2018) Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radiol Med 123(9):719–725CrossRefPubMed

De Bari B, Arcangeli S, Ciardo D, Mazzola R, Alongi F, Russi EG, Santoni R, Magrini SM, Jereczek-Fossa BA (2016) Extreme hypofractionation for early prostate cancer: Biology meets technology. Cancer Treat Rev 50:48–60. https://doi.org/10.1016/j.ctrv.2016.08.005 CrossRefPubMed

Valeriani M, Carnevale A, Agolli L, Bonome P, Montalto A, Nicosia L, Osti MF, De Sanctis V, Minniti G, Maurizi Enrici R (2014) Image-guided hypofractionated radiotherapy in low-risk prostate cancer patients. Biomed Res Int. https://doi.org/10.1155/2014/465175 CrossRefPubMedPubMedCentral

Nicosia L, Mazzola R, Rigo M, Figlia V, Giaj-Levra N, Napoli G, Ricchetti F, Corradini S, Ruggieri R, Alongi F (2019) Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol 145(10):2547–2554. https://doi.org/10.1007/s00432-019-02983-3 CrossRefPubMed

Créhange G, Roach M 3rd, Martin E, Cormier L, Peiffert D, Cochet A, Chapet O, Supiot S, Cosset JM, Bolla M, Chung HT (2014) Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how? Cancer Radiother 18(5-6):524–534. https://doi.org/10.1016/j.canrad.2014.07.153 CrossRefPubMed

Alongi F, De Bari B, Campostrini F, Arcangeli S, Matei DV, Lopci E, Petralia G, Bellomi M, Chiti A, Magrini SM, Scorsetti M, Orecchia R, Jereczek-Fossa BA (2013) Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: a review. Crit Rev Oncol Hematol 88(3):550–563. https://doi.org/10.1016/j.critrevonc.2013.07.009 CrossRefPubMed

Cooperberg MR, Vickers AJ, Broering JM, Carroll PR (2010) Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226–5234CrossRefPubMed

10.

Murota-Kawano A, Nakano M, Hongo S, Shoji S, Nagata Y, Uchida T (2010) Salvage high-intensity focused ultrasound for biopsy-confirmed local recurrence of prostate cancer after radical prostatectomy. BJU Int 105(12):1642–1645. https://doi.org/10.1111/j.1464-410X.2009.08990.x CrossRefPubMed

11.

Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML et al (2011) Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 60:205–210. https://doi.org/10.1016/j.eururo.2011.03.011 CrossRefPubMedPubMedCentral

12.

De Bari B, Fiorentino A, Arcangeli S, Franco P, D’Angelillo RM, Alongi F (2014) From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Rev Anticancer Ther 14(5):553–564. https://doi.org/10.1586/14737140.2014.883282 CrossRefPubMed

13.

Mariucci C, Ingrosso G, Bini V, Saldi S, Lupattelli M, Frattegiani A, Perrucci E, Palumbo I, Falcinelli L, Centofanti G, Bellavita R, Aristei C (2020) Helical tomotherapy re-irradiation for patients affected by local radiorecurrent prostate cancer. Rep Pract Oncol Radiother 25(2):157–162. https://doi.org/10.1016/j.rpor.2020.01.005 CrossRefPubMedPubMedCentral

14.

Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni S, Nicita G, Livi L (2016) CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed. World J Urol 34(3):311–317. https://doi.org/10.1007/s00345-015-1613-5 CrossRefPubMed

15.

Vavassori A, Jereczek-Fossa BA, Beltramo G, De Cicco L, Fariselli L, Bianchi LC, Possanzini M, Bergantin A, DeCobelli O, Orecchia R (2010) Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases. Tumori 96(1):71–75CrossRefPubMed

16.

Jereczek-Fossa BA, Rojas DP, Zerini D, Fodor C, Viola A, Fanetti G, Volpe S, Luraschi R, Bazani A, Rondi E, Cattani F, Vavassori A, Garibaldi C, Alessi S, Pricolo P, Petralia G, Cozzi G, De Cobelli O, Musi G, Orecchia R, Marvaso G, Ciardo D (2019) Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). Br J Radiol 92(1094):20180494. https://doi.org/10.1259/bjr.20180494 CrossRefPubMed

17.

Fuller D, Wurzer J, Shirazi R, Bridge S, Law J, Crabtree T, Mardirossian G (2020) Retreatment for local recurrence of prostatic carcinoma after prior therapeutic irradiation: efficacy and toxicity of HDR-like SBRT. Int J Radiat Oncol Biol Phys 106(2):291–299. https://doi.org/10.1016/j.ijrobp.2019.10.014 CrossRefPubMed

18.

Zerini D, Jereczek-Fossa BA, Fodor C, Bazzani F, Maucieri A, Ronchi S, Ferrario S, Colangione SP, Gerardi MA, Caputo M, Cecconi A, Gherardi F, Vavassori A, Comi S, Cambria R, Garibaldi C, Cattani F, De Cobelli O, Orecchia R (2015) Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer. Br J Radiol 88(1052):20150197. https://doi.org/10.1259/bjr.20150197 CrossRefPubMedPubMedCentral

19.

Arcangeli S, Gambardella P, Agolli L, Monaco A, Dognini J, Regine G, Donato V (2015) Stereotactic body radiation therapy salvage reirradiation of radiorecurrent prostatic carcinoma relapsed in the prostatic bed. Tumori 101(2):e57–e59. https://doi.org/10.5301/tj.5000251 CrossRefPubMed

20.

Olivier J, Basson L, Puech P, Lacornerie T, Villers A, Wallet J, Lartigau E, Pasquier D (2019) Stereotactic re-irradiation for local recurrence in the prostatic bed after prostatectomy: preliminary results. Front Oncol 15(9):71. https://doi.org/10.3389/fonc.2019.00071 CrossRef

21.

Ingrosso G, Becherini C, Lancia A, Caini S, Ost P, Francolini G, Høyer M, Bottero M, Bossi A, Zilli T, Scartoni D, Livi L, Santoni R, Giacomelli I, Detti B (2019) Nonsurgical salvage local therapies for radiorecurrent prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. https://doi.org/10.1016/j.euo.2018.12.011 CrossRefPubMed

22.

Rigo M, Mazzola R, Napoli G, Giaj-Levra N, Figlia V, Nicosia L, Ricchetti F, Tomasini D, Bonù ML, Cuccia F, Bellorofonte C, Alongi F (2020) Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiol Med. https://doi.org/10.1007/s11547-020-01148-4 CrossRefPubMed

23.

Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF (2018) The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis 21(1):4–21. https://doi.org/10.1038/s41391-017-0007-8 CrossRefPubMed

24.

Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, Oncology NRGRTOG (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376(5):417–428. https://doi.org/10.1056/NEJMoa1607529 CrossRefPubMedPubMedCentral

25.

Alongi F, Mazzola R, Fiorentino A, Corradini S, Aiello D, Figlia V, Gregucci F, Ballario R, Cavalleri S, Ruggieri R (2019) Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlenther Onkol 195(2):113–120. https://doi.org/10.1007/s00066-018-1338-7 CrossRefPubMed

26.

Ramey SJ, Marshall DT (2013) Re-irradiation for salvage of prostate cancer failures after primary radiotherapy. World J Urol 31:1339–1345CrossRefPubMed

27.

Chatzikonstantinou G, Zamboglou N, Ro¨del C et al (2017) High-dose-rate brachytherapy as salvage modality for locally recurrent prostate cancer after definitive radiotherapy. Strahlenther Onkol 193:683–691CrossRefPubMed

28.

Zilli T, Benz E, Dipasquale G, Rouzaud M, Miralbell R (2016) Reirradiation of prostate cancer local failures after previous curative radiation therapy: long-term outcome and tolerance. Int J Radiat Oncol Biol Phys 96(2):318–322. https://doi.org/10.1016/j.ijrobp.2016.05.024 CrossRefPubMed

29.

Rutenberg MS, Meister M, Amin PP, Hussain A, Naslund MJ, Kwok Y (2016) Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy. Brachytherapy 15(6):722–729. https://doi.org/10.1016/j.brachy.2016.08.004 CrossRefPubMed

30.

Loi M, Di Cataldo V, Simontacchi G, Detti B, Bonomo P, Masi L, Desideri I, Greto D, Francolini G, Carfora V, Pezzulla D, Perna M, Carta GA, Livi L (2018) Robotic stereotactic retreatment for biochemical control in previously irradiated patients affected by recurrent prostate cancer. Clin Oncol (R Coll Radiol) 30(2):93–100. https://doi.org/10.1016/j.clon.2017.11.007 CrossRef

31.

Janoray G, Reynaud-Bougnoux A, Ruffier-Loubiere A et al (2016) Reirradiation stereotaxique robotisee de recidive locale de cancer de prostate apres radiotherapie externe: Resultats preliminaires. Cancer Radiother 20:275–281CrossRefPubMed

32.

Mbeutcha A, Chauveinc L, Bondiau PY et al (2017) Salvage prostate reirradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol 12:1–10CrossRef

33.

Pasquier D, Martinage G, Janoray G, Rojas DP, Zerini D, Goupy F, De Crevoisier R, Bogart E, Calais G, Toledano A, Chauveinc L, Scher N, Bondiau PY, Hannoun-Levi JM, Silva M, Meyer E, Nickers P, Lacornerie T, Jereczek-Fossa BA, Lartigau E (2019) Salvage stereotactic body radiation therapy for local prostate cancer recurrence after radiation therapy: a retrospective multicenter study of the GETUG. Int J Radiat Oncol Biol Phys 105(4):727–734. https://doi.org/10.1016/j.ijrobp.2019.07.012 CrossRefPubMed

34.

D’Agostino GR, Di Brina L, Mancosu P, Franzese C, Iftode C, Franceschini D, Clerici E, Tozzi A, Navarria P, Scorsetti M (2019) Reirradiation of locally recurrent prostate cancer with volumetric modulated arc therapy. Int J Radiat Oncol Biol Phys 104(3):614–621. https://doi.org/10.1016/j.ijrobp.2019.02.041 CrossRefPubMed

35.

Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A, Maranzano E, Lohr F, D’Angelillo R, Magli A, Bonetta A, Mazzola R, Pasinetti N, Francolini G, Ingrosso G, Trippa F, Fersino S, Borghetti P, Ghirardelli P, Magrini SM (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116(12):1520–1525. https://doi.org/10.1038/bjc.2017.103 CrossRefPubMedPubMedCentral

36.

Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D’agostino G, Corradini S, Alongi F, Scorsetti M (2020) Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol 196(3):213–221. https://doi.org/10.1007/s00066-019-01523-9 CrossRefPubMed

37.

Alongi F, Fersino S, Giaj Levra N, Mazzola R, Ricchetti F, Fiorentino A, Ruggieri R, Malfatti V, Cavalleri S, Salgarello M (2015) Impact of 18F-choline PET/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med 40(11):e496–e500CrossRefPubMed

38.

Donaldson IA, Alonzi R, Barratt D, Barret E, Berge V, Bott S, Bottomley D, Eggener S, Ehdaie B, Emberton M, Hindley R, Leslie T, Miners A, McCartan N, Moore CM, Pinto P, Polascik TJ, Simmons L, van der Meulen J, Villers A, Willis S, Ahmed HU (2015) Focal therapy: patients, interventions, and outcomes—a report from a consensus meeting. Eur Urol 67(4):771–777. https://doi.org/10.1016/j.eururo.2014.09.018 CrossRefPubMedPubMedCentral

39.

Kaljouw E, Pieters BR, Kova’cs G et al (2016) A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. Radiother Oncol 118:122–130CrossRefPubMed

Title: Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer
Authors: Dr. Francesco Cuccia
Luca Nicosia
Rosario Mazzola
Vanessa Figlia
Niccolò Giaj-Levra
Francesco Ricchetti
Michele Rigo
Claudio Vitale
Stefanie Corradini
Ruggero Ruggieri
Filippo Alongi
Publication date: 01-07-2020
Publisher: Springer Berlin Heidelberg
Keywords: Prostate Cancer
Brachytherapy
Prostate Cancer
Radiotherapy
Published in: Strahlentherapie und Onkologie / Issue 7/2020
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-020-01628-6

At a glance: The STEP trials

Springer Medicine

Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer

Abstract

Background and objective

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background and objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2020

Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities

Intensitätsmodulierte fraktionierte Radiotherapie vs. körperstereotaktische Radiotherapie des Prostatakarzinoms (PACE-B) – akute Toxizität aus einer internationalen, randomisierten Phase-III-Nichtunterlegenheitsstudie

Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer

An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report

PSMA-positive nodal recurrence in prostate cancer

Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer